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Objectives. This study examined the relations of echocardio-
graphically determined left ventricular (LV) mass and hypertro-
phy to the risk of sudden death.
Background. Echocardiographic LV hypertrophy is associated
with increased risk for all-cause mortality and cardiovascular disease
morbidity and mortality. However, little is known about the associ-
ation of echocardiographic LV hypertrophy with sudden death.
Methods. We examined the relations of LV mass and hypertro-
phy to the incidence of sudden death in 3,661 subjects enrolled in
the Framingham Heart Study who were >240 years of age. The
baseline examination was performed from 1979 to 1983 and LV
hypertrophy was defined as LV mass (adjusted for height)
>143 g/m in men and >102 g/m in women. During up to 14 years
of follow-up there were 60 sudden deaths. Cox models examined
the relations of LV mass and LV hypertrophy to sudden death risk
after adjusting for known risk factors.
Results. The prevalence of LV hypertrophy was 21.5%. The risk
factor–adjusted hazard ratio (HR) for sudden death was 1.45
(95% confidence interval [CI] 1.10 to 1.92, p 5 0.008) for each
50-g/m increment in LV mass. For LV hypertrophy, the risk
factor–adjusted HR for sudden death was 2.16 (95% CI 1.22 to
3.81, p 5 0.008). After excluding the first 4 years of follow-up, both
increased LV mass and LV hypertrophy conferred long-term risk
of sudden death (HR 1.53, 95% CI 1.01 to 2.28, p 5 0.047 and HR
3.28, 95% CI 1.58 to 6.83, p 5 0.002, respectively).
Conclusions. Increased LV mass and hypertrophy are associ-
ated with increased risk for sudden death after accounting for
known risk factors.
(J Am Coll Cardiol 1998;32:1454–9)
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Sudden death is a leading public health problem and, despite
a continuing decline in cardiovascular disease mortality, there
are 300,000 sudden deaths annually (1). Although there have
been many advances in sudden death research, there has been
limited impact on the incidence of sudden death (2). Preven-
tion of sudden death may require a better understanding of its
pathophysiologic mechanisms and predisposing factors.
See page 1460
Previous studies have documented high rates of adverse
cardiovascular events in subjects with left ventricular (LV)
hypertrophy (3–11). It has been consistently shown that LV
hypertrophy on the electrocardiogram is strongly associated
with increased risk for multiple manifestations of coronary
heart disease, including sudden death (5–7,9,12–14). Echocar-
diographic LV hypertrophy also has been reported to be
associated with increased risk for cardiovascular disease and
all-cause mortality in hospital- and clinic-based studies
(8,10,11,15–17) and in population-based investigations (3,4).
The association of echocardiographic LV mass and hypertro-
phy with risk for sudden death has not been thoroughly examined
in a free-living population. This study was undertaken to extend a
previous study that suggested an increased risk for sudden death
in subjects with LV hypertrophy on the echocardiogram (3).
Methods
Study population and outcome events. Since 1948 the
Framingham Heart Study has followed participants at regular
intervals as part of a prospective population-based investiga-
tion of cardiovascular disease. Study design and recruitment
procedures have been published previously (18); 5,209 men
and women aged 28 to 62 years were enrolled. Every 2 years a
follow-up visit included a medical history, physical examina-
tion, blood pressure measurements, 12-lead electrocardiogram
and laboratory tests. Beginning in 1971 the Framingham
Offspring Study enrolled 5,124 men and women who were
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offspring or spouses of offspring of original Framingham Heart
Study subjects (19). The second through fifth Framingham
Offspring Study examinations were conducted 8, 12, 16 and 20
years, respectively, after the initial examination cycle.
Methodology for assessing risk factors has been published
previously (18,19). Age, gender, height, weight, blood pressure,
antihypertensive medication use, total and high density li-
poprotein cholesterol, diabetes mellitus, and cigarette smoking
were routinely obtained for each participant. Body mass index
(kilograms/square meter) was used as a measure of obesity.
Sitting systolic and diastolic blood pressures were measured
twice by a physician using a mercury column sphygmomanom-
eter and averaged. Serum cholesterol was measured by the
Abell–Kendal method. Diabetes was diagnosed if subjects
were under treatment for diabetes, if they had a record of an
abnormal glucose tolerance test or if they had a random blood
glucose level of 150 mg/100 ml or more on at least two
examinations (20). Participants were categorized as smokers if
they currently smoked cigarettes or if they had quit within 1
year before the clinic examination. Coronary heart disease and
congestive heart failure were routinely assessed at each exam-
ination, and suspected events were reviewed by a panel of
three physicians. Criteria for congestive heart failure and
coronary heart disease have been described previously (20). A
diagnosis of congestive heart failure was made if at least two
major criteria or one major and two minor criteria were met
(20). Coronary heart disease was diagnosed if subjects had a
history of myocardial infarction, coronary insufficiency or
angina pectoris (20). Electrocardiographic LV hypertrophy
was present when increased voltage was associated with major
ST-T repolarization changes (strain pattern) (6,20).
Because of the low incidence of sudden death in young
subjects, this study was restricted to those study participants
who were $40 years of age at the baseline examination
conducted from 1979 to 1983. All deaths were reviewed and
probable cause was established by a committee of three
physicians after a review of hospital records, autopsy findings,
death certificates and interviews with family members. If a
subject, apparently well, died within 1 h of onset of symptoms,
and if the cause of death could not reasonably be attributed, on
the basis of the full clinical information and the information
concerning death, to some potentially lethal disease other than
coronary heart disease, this was called sudden death and was
attributed to coronary heart disease (20).
Echocardiographic methods. Subjects were studied with
M-mode echocardiography as described previously (21). Mea-
surements of the internal diameter and wall thickness of the
left ventricle were made at end diastole according to the
methods of Devereux and Reichek (22). Left ventricular mass
was calculated with the following formula: LV mass (in grams)
5 1.04 [(LVID 1 VST 2 PWT)3] 2 13.6, where LVID denotes
the LV internal diameter, VST the ventricular septal thickness
and PWT the posterior wall thickness. To correct for differ-
ences in heart size in subjects of different body size, LV mass
(in grams) was divided by height (in meters) because of the
association observed between LV mass and height in a healthy
reference group (21). Left ventricular hypertrophy was defined
as an LV mass two or more standard deviations above the
mean for the healthy reference group. The cutoff values for LV
hypertrophy were 143 g/m in men and 102 g/m in women (21).
Statistical analysis. Subjects were followed for up to 14
years after the initial echocardiographic examination. The
incidence of sudden death was examined both as a function of
increments in LV mass (adjusted for height) and as a function
of the presence or absence of LV hypertrophy.
Crude incidence rates for sudden death were displayed for
men and women according to quartiles of LV mass adjusted
for height and according to LV hypertrophy status. The Cox
proportional hazards model was used to examine these rela-
tions using several covariates chosen by stepwise selection (23).
These were age, gender, antihypertensive treatment, smoking
status, high-density lipoprotein cholesterol, diabetes mellitus
and presence of coronary heart disease or congestive heart
failure. Systolic blood pressure, diastolic blood pressure, total
cholesterol and body mass index did not enter the stepwise
models and therefore were not included as covariates in the
final models. Risk factor–adjusted hazard ratios (HR) and 95
percent confidence intervals (CI) were calculated for every
increment of 50 g/m in LV mass and for the presence (vs.
absence) of LV hypertrophy.
Proportional hazards assumptions were verified by graphic
displays and Cox models that included time-dependent inter-
action terms to permit HRs to increase or decrease as duration
of follow-up increased. There were too few sudden deaths
among women to test whether the relation of LV mass with
sudden death was the same in both sexes; instead, we con-
ducted a secondary analysis in men only. Because LV mass is
associated with all manifestations of coronary heart disease,
the development of myocardial infarction before sudden death
in those with and without LV hypertrophy was also examined.
A p value ,0.05 was considered significant. Statistical analysis
was performed using SAS software (24).
Results
Of the 4,853 men and women above 40 years of age who
were seen at the baseline examination, an echocardiogram of
adequate quality to measure LV mass was available for 3,663
subjects (75.5%). Those who had inadequate echocardiograms
were older and more obese and had higher rates of sudden
death compared with those with adequate echocardiograms
(4.6 vs. 2.9 per 1,000 person-years of follow-up in men;
corresponding rates in women were 1.1 vs. 0.5). Two subjects
who had no follow-up contact were excluded from analysis.
The study sample comprised 3,661 subjects (1,634 men and
Abbreviations and Acronyms
CI 5 confidence interval
HR 5 hazard ratio
LV 5 left ventricular
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2,027 women) with a mean age of 57 6 11 years. The
characteristics of the study subjects are summarized in Table 1.
Echocardiographic criteria for LV hypertrophy were fulfilled
in 304 men (19%) and 477 women (24%).
In the study cohort 18% of men and 23% of women were
receiving antihypertensive treatment. Among subjects without
echocardiographic LV hypertrophy, 5% were taking beta-
adrenergic blocking agents, 14% diuretics and 7% other agents
for treatment of hypertension; 18% were being treated with at
least one of these agents and 7% with two or more. In contrast,
among subjects with echocardiographic LV hypertrophy, 13%
were taking beta blockers, 29% diuretics and 19% other agents
for treatment of hypertension; 42% were being treated with at
least one of these agents and 16% with two or more.
During follow-up (mean 10.32 years, range 0.00 to 14.41
years) sudden death occurred in 49 men (mean age 70.5 6 11.5
years) and in 11 women (mean age 75 6 9.4 years). Unadjusted
sudden death rates per 1,000 person-years of follow-up ranged
from 1.1% in men with an LV mass ,95 g/m to 6.9% in those
with values .135 g/m; the corresponding rates for women were
0% and 1.0%, respectively (Fig. 1). The age-, gender- and risk
factor–adjusted HR for sudden death per 50-g/m increment in
LV mass was 1.45 (95% CI 1.10 to 1.92, p 5 0.008, Table 2).
The rates of sudden death in men with LV hypertrophy and
in those without were 8.2 and 1.9 per 1,000 person-years,
respectively. The corresponding rates for women were 0.9%
and 0.4% (Fig. 2). Among subjects with LV hypertrophy the
age-, gender- and risk factor–adjusted HR for sudden death
was 2.16 (95% CI 1.22 to 3.81, p 5 0.008, Table 3). The
frequency of interim myocardial infarction in sudden death
victims with and without LV hypertrophy was 28% and 20%,
respectively. In secondary analyses of men only, the associa-
tions of LV mass and LV hypertrophy with sudden death risk
were stronger than in the analyses with both sexes combined
(Tables 2 and 3).
A pattern of electrocardiographic LV hypertrophy with
repolarization abnormality (strain pattern) was uncommon.
Only 47 subjects (1.3%) had definite electrocardiographic LV
hypertrophy; 39 (83.0%) of these also had echocardiographic
LV hypertrophy and 3 (6.4%) had sudden death. In contrast,
Figure 1. Incidence (unadjusted) of sudden death ac-
cording to quartiles of LV mass (adjusted for height).
Quartile partition values for LV mass were: Q1,
,95 g/m in men and ,70 g/m in women; Q2, 95 to 109
and 70 to 84; Q3, 110 to 134 and 85 to 99; Q4, $135 and
$100.
Table 1. Baseline Characteristics of the Study Sample
Men (n 5 1,634) Women (n 5 2,027)
Age (yrs) 56 6 10.8 (40–88) 58 6 11.8 (40–91)
Body mass index (kg/m2) 26.7 6 3.5 (15.5–42.7) 25.5 6 4.6 (15.6–49.5)
Systolic blood pressure
(mm Hg)
132 6 18 (92–225) 130 6 20 (84–278)
Diastolic blood pressure
(mm Hg)
81 6 9 (50–140) 77 6 10 (40–143)
Antihypertensive
treatment (%)
18 23
Coronary disease or heart
failure (%)
11 8
Diabetes mellitus (%) 8 5
Cigarette smoker (%) 30 30
Total cholesterol (mg/dl) 213 6 38 (93–421) 221 6 39 (52–511)
HDL cholesterol (mg/dl) 43 6 12 (16–119) 55 6 15 (18–112)
LV mass (g/m) 119 6 38 (37–518) 89 6 30 (33–439)
LV hypertrophy (%) 19 24
Values are means 6 SD (range). HDL 5 high-density lipoprotein; LV 5 left
ventricular.
Table 2. Left Ventricular Mass and Risk of Sudden Death
Hazard
Ratio*
95% Confidence
Interval
Lower Upper
Unadjusted 1.94 1.66 2.27
Age and sex adjusted 1.50 1.19 1.89
Age, sex and risk factor† adjusted 1.45 1.10 1.92
Age and risk factor† adjusted, men only 1.57 1.18 2.09
*Hazard ratio per 50 g/m increment in left ventricular mass. †Risk factors:
age, gender, antihypertensive treatment, smoking status, high-density lipoprotein
cholesterol, diabetes mellitus, coronary heart disease or congestive heart failure.
1456 HAIDER ET AL. JACC Vol. 32, No. 5
LV MASS AND SUDDEN DEATH November 1, 1998:1454–9
among subjects without electrocardiographic LV hypertrophy,
736 (20.4%) had echocardiographic LV hypertrophy and 57
(1.6%) had sudden death. In a secondary analysis, when
electrocardiographic LV hypertrophy was included as a covari-
ate in the multivariable model, the HRs for echocardiographic
LV hypertrophy and LV mass were essentially unchanged (HR
2.13, 95% CI 1.19 to 3.80, p 5 0.011 and HR 1.43, 95% CI 1.07
to 1.89, p 5 0.015, respectively).
There were 27 sudden deaths in the first 4 years of
follow-up and 33 thereafter. Neither LV mass (HR 1.34/50 g
per m, 95% CI 0.91 to 1.98, p 5 0.14) nor LV hypertrophy (HR
1.08, 95% CI 0.44 to 2.69, p 5 0.86) conferred significant risk
during the first 4 years of follow-up. After excluding the first 4
years of follow-up, risk of sudden death was substantially
increased in the long term, both for increased LV mass (HR
1.53/50 g per m, 95% CI 1.01 to 2.28, p 5 0.047) and in
association with LV hypertrophy (HR 3.28, 95% CI 1.58 to
6.83, p 5 0.002).
Discussion
Prognostic implications of LV hypertrophy and increased
LV mass. Previous studies have reported an increased risk for
cardiovascular disease in subjects with echocardiographic evi-
dence of LV hypertrophy (3,4,8,10,11,14–17,25–29). Studies
from Framingham and elsewhere have demonstrated an asso-
ciation between echocardiographically determined LV mass
and the risk for coronary heart disease in middle-aged and
elderly subjects (3,4,30). However, the association of echocar-
diographic LV hypertrophy with sudden death has not been
examined thoroughly in a general population sample. This
study was undertaken to examine the associations of LV mass
and LV hypertrophy with sudden death risk in a large group of
middle-aged and elderly subjects enrolled in the Framingham
Heart Study. This long-term follow-up study of a carefully
monitored cohort supports the hypothesis that LV hypertrophy
is an independent risk factor for sudden death and the hazards
increase with increasing LV mass. With a mean follow-up of
10.32 years, this study also demonstrates that LV hypertrophy
confers long-term risk for sudden death. These findings may
enhance our understanding of pathophysiologic mechanisms
and predisposing factors for sudden death.
Left ventricular hypertrophy on the electrocardiogram is
well known to predict morbidity and mortality both in the
general population and in patients with hypertension (5–
7,9,12–14). Individuals with electrocardiographic evidence of
LV hypertrophy also have been shown to be at increased risk
for sudden death (14,31,32). Electrocardiographic LV hyper-
trophy was found to be a short- and long-term predictor of
sudden death in a previous study from Framingham (32). The
association persists after taking into account the traditional
coronary disease risk factors that may have promoted LV
hypertrophy (14,32).
Electrocardiographic criteria for LV hypertrophy that are
based on voltage and repolarization abnormalities have high
specificity but low sensitivity for the detection of echocardio-
graphic LV hypertrophy (25,26,28,33,34). Echocardiography
has provided an accurate, noninvasive means of estimation of
LV mass and has proved to be a more reliable tool for the
detection of LV hypertrophy (25,33–35). In this study the
application of gender-specific criteria for LV hypertrophy,
Figure 2. Incidence (unadjusted) of sudden
death in men and women according to LV
hypertrophy status. The cutoff values for LV
hypertrophy were 143 g/m in men and 102 g/m
in women (21).
Table 3. Left Ventricular Hypertrophy and Risk of Sudden Death
Hazard
Ratio*
95% Confidence
Interval
Lower Upper
Unadjusted 3.40 2.04 5.66
Age and sex adjusted 2.63 1.56 4.45
Age, sex and risk factor† adjusted 2.16 1.22 3.81
Age and risk factor† adjusted, men only 2.89 1.56 5.38
*Hazard ratio comparing subjects with and those without left ventricular
hypertrophy. †Risk factors: age, gender, antihypertensive treatment, smoking
status, high-density lipoprotein cholesterol, diabetes mellitus, coronary heart
disease or congestive heart failure.
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based on the distribution of LV mass in a healthy reference
sample (21), revealed a prevalence of LV hypertrophy of 19%
in men and 24% in women.
Potential mechanisms. The mechanisms by which cardiac
hypertrophy may increase risk for sudden death are inade-
quately understood. Left ventricular hypertrophy reduces cor-
onary flow reserve while increasing myocardial oxygen con-
sumption (36,37). This imbalance also may predispose to
ischemia (38), arrhythmias (39 – 41) and sudden death
(3,15,39,40,42,43). Coronary blood supply also may be im-
paired by atherosclerosis in persons with LV hypertrophy
because some factors associated with myocardial hypertrophy
are atherogenic. Studies in laboratory animals with hyperten-
sive LV hypertrophy have demonstrated a threefold risk of
sudden death as well as increased myocardial infarct size after
coronary occlusion (44–46). Moreover, hypertensive LV hy-
pertrophy is associated with vascular hypertrophy and subclin-
ical disease, which may increase the consequences of coronary
artery obstruction (45,47,48).
The correlation between heart weight and severity of cor-
onary heart disease in sudden death victims is not strong (49);
heart weights are higher in sudden death victims than in those
with nonsudden death, despite a similar prevalence of hyper-
tension before death (50). Cooper et al. (16) and Ghali et al.
(51) documented that increased LV mass predicts subsequent
mortality more strongly in patients without angiographic evi-
dence of obstructive coronary artery disease than in those with
stenosis of epicardial coronary arteries. These findings have
been interpreted to suggest that LV mass reflects the inte-
grated adverse effects on the heart of increased hemodynamic
load and vascular damage.
The small number of sudden deaths in women may partly
reflect the definition used for sudden death (e.g. witnessed
death). The mean age of sudden death cases was 70.5 years in
men and 75.4 years in women. The older age at sudden death
in women implies that a greater proportion of women than
men would have outlived their spouse; consequently, witnessed
sudden death would have been difficult to document in these
circumstances. Our observations are also consistent with pre-
vious studies that sudden death has a preponderance in men
compared with women (14,52). A 3.8-fold incidence of sudden
death in men compared with women at 20 years of follow-up
was reported in Framingham Heart Study participants (52).
Strengths and limitations. The Framingham Heart Study
provides a large sample in which risk factors are routinely
assessed at periodic examination cycles. The study includes
both men and women and consists of a population-based
sample in which referral bias is inherently low. Some limita-
tions of the present study need to be considered. Left ventric-
ular mass was assessed using M-mode echocardiography,
which may misclassify subjects in the setting of abnormal LV
geometry. Because of the largely Caucasian composition of the
study sample, these findings may not be generalizable to other
groups. Over a long follow-up period (mean 10.32 years) a
single baseline assessment of LV hypertrophy may lose its
prognostic value because of alterations in LV mass over time.
However, baseline LV mass remained predictive of increased
long-term risk of sudden death in this study. Further studies
are warranted to examine the association of serial changes in
LV mass with sudden death, because in previous studies, an
increase in LV hypertrophy on the electrocardiogram (13) or
echocardiogram (53) was predictive of adverse outcomes com-
pared with no change or a decrease. This is an observational
study and outside physicians selected antihypertensive therapy
according to their patients’ characteristics; this may introduce
bias. Finally, a considerable number of subjects (24.5%) were
excluded from this study because of inadequate quality of
echocardiograms. The cumulative incidence of sudden death
for subjects with inadequate echocardiograms was 2.2%, an
intermediate value between those with LV hypertrophy and
those without LV hypertrophy (3.1% and 0.8%, respectively).
Therefore, it is not likely that the inability to obtain adequate
echocardiograms in the entire study sample materially affected
the conclusions of this investigation.
Conclusions. Increased LV mass and hypertrophy on the
echocardiogram are associated with increased risk for sudden
death after accounting for other known coronary disease risk
factors. To our knowledge this is the first study demonstrating
a long-term association between LV mass and sudden death in
a community-based cohort. It is unclear whether antihyperten-
sive therapies that promote regression of LV hypertrophy will
reduce the risk for sudden death. Left ventricular hypertrophy,
however, was not always an indication of coexisting hyperten-
sion in our study participants. Clinical trials are underway to
assess the benefits of LV hypertrophy regression.
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